Adimmune Corporation (4142) Fair Value & Analysis
Healthcare · TW · Market cap 7.5B TWD
Fair value as of: Jul 11, 2026
From 3 valuation models · updated today
Fair value updated Jul 11, 2026 — revised from 52.79 TWD to 11.12 TWD (−78.9%) since Jun 24, 2026. Share price +0.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 16.00 TWD – 21.55 TWD · fair‑value band 4.99 TWD – 19.20 TWD · the 17.65 TWD price screens above the 11.12 TWD fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Adimmune Corporation (4142) currently trades at 17.65 TWD, while our model-based Fair Value estimate is 11.12 TWD — implying the stock looks roughly 37.0% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Adimmune Corporation generated revenue of 1.4B TWD at a net margin of -14.3%. Revenue grew 14.2% year over year. It earns a return on equity of -5.4%. Net debt stands at 644M TWD. Fundamentals as of Jul 11, 2026
Our scenario range runs from 4.99 TWD (bear case) to 19.20 TWD (bull case); at 17.65 TWD, the current price sits within that range. The share trades about 22% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -37%, 4142 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Adimmune Corporation reported revenue of 1.4B TWD in FY2025 versus 1.6B TWD in FY2021, a compound −3.9%/yr. Reported net income was −240M TWD in FY2025.
Is 4142 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Adimmune Corporation (4142) undervalued?
What is the fair value of 4142?
What is the quality score of 4142?
What is the revenue of Adimmune Corporation (4142)?
What is the net profit margin of 4142?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.